This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor gene mutations, which are present in approximately 10% of non-small cell lung cancers.
Read More
Data published in Journal of Thoracic Oncology.
Read More
The platform offers clinicians a way to automatically perform genetic analysis on tissue samples, stained with the Abbott ALK probe kit, and identify the ALK gene rearrangement.
Read More
The test detects all types and all stages of lung cancer, including Stage I and II.
Read More
Life Technologies Corp, Carlsbad, Calif, announced publication of a study that underscores the clinical utility of the company’s early stage lung cancer test.
Read More